NGR-hTNF: Interim Phase II data

Interim data from 55 evaluable patients in the open-label, European Phase II Study NGR016 trial showed that weekly IV infusions of 0.8 µg/m 2 NGR-hTNF in combination with doxorubicin (Arm C)

Read the full 315 word article

How to gain access

Continue reading with a
two-week free trial.